Login
Search
Search
0 Dates
2026
2025
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
CPC 2025
CPC 2026
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Sixteen-Year Follow-Up of Cardiac Sarcoidosis in a Southern Europe population: Clinical Outcomes and Prognostic Insights
Session:
Sessão de Posters 21 - Por dentro do miocárdio: da genética aos resultados
Speaker:
Pedro Miguel Ventura
Congress:
CPC 2026
Topic:
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
Theme:
17. Myocardial Disease
Subtheme:
17.2 Myocardial Disease – Epidemiology, Prognosis, Outcome
Session Type:
Posters Eletrónicos
FP Number:
---
Authors:
Pedro Miguel Ventura; Mariana Salvador; João Borges-Rosa; Rodolfo Silva; Lino Gonçalves; Gracinda Costa; Maria João Vidigal Ferreira
Abstract
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><strong>Background:</strong> Sarcoidosis is a granulomatous disease of unknown cause, and cardiac involvement occurs in a minority of patients. Cardiac sarcoidosis (CS) may lead to conduction disturbances, ventricular arrhythmias, heart failure (HF), or even sudden death, though many cases remain asymptomatic.</span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><strong>Purpose:</strong> To evaluate the long-term clinical outcomes of patients with suspected CS in a Southern European population over a 16-year follow-up period.</span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><strong>Methods:</strong> We reviewed all [18F]FDG-Positron Emission Tomography (PET) reports of patients assessed for suspected sarcoidosis from 2009-2025. Patients with biopsy-confirmed sarcoidosis were evaluated using Hearth Rhythm Society (HRS) criteria to identify probable cardiac involvement. The primary outcome was a composite of HF hospitalization, arrhythmias requiring intervention, pacemaker implantation for complete heart block, and all-cause mortality.</span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><strong>Results:</strong> Out of 960 [18F]FDG-PET scans, 314 patients had histologically confirmed extracardiac sarcoidosis. Of these, 27 (8.6%; 41% female; mean age 58.8 ± 13.2 years) were classified as probable cardiac sarcoidosis per HRS criteria, based on [18F]FDG-PET (n = 15), cardiovascular magnetic resonance (CMR) (n = 11), or unexplained LVEF <40% (n = 1). Most patients had no cardiac symptoms (59.3%) during follow-up, and atrial fibrillation occurred in 29.6%, while coronary artery disease and significant valvular disease each occurred in 7.4%. After a median follow-up of 43 [17-104] months, the composite outcome occurred in eleven patients (40.7%): 22.2% had HF hospitalizations; 22.2% had uncontrolled arrythmia requiring intervention (three titration of betablockers due to high burden of premature ventricular complex / non-sustained ventricular tachycardia (VT), two atrial flutter ablation, and one implanted cardiac resynchronization therapy with a defibrillator (CRT-D) due to non-sustained VT and left ventricle systolic disfunction); 14.8% implanted a pacemaker due to complete heart block at a median age of 66 [58-72] years. Additionally, five-patients (18.5%) died during follow-up, two of cardiovascular causes (HF and intestinal ischemia). </span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><strong>Conclusions:</strong> Probable cardiac involvement was identified in 8.3% of this Southern European extracardiac sarcoidosis cohort, mostly occurring in asymptomatic patients. Over a median follow-up of 3.6 years, nearly half of the patients experienced major adverse events highlighting the need for vigilant cardiac monitoring in this population.</span></span></p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site